Steven Pieper - 28 Jul 2021 Form 4 Insider Report for XERIS PHARMACEUTICALS INC

Reporting relationship: Chief Financial Officer
Issuer ticker: N/A
Reported as of: 28 Jul 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 29 Jul 2021, 18:06:37 UTC
Next SEC filing: 05 Oct 2021
Source filing: View source filing
Reporting owner signature: /s/ Beth Hecht, as Attorney-in-Fact

Key filing fact

Steven Pieper filed Form 4 for XERIS PHARMACEUTICALS INC on 29 Jul 2021.

Key facts

This page summarizes Steven Pieper's Form 4 filing for XERIS PHARMACEUTICALS INC.
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 29 Jul 2021, 18:06.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

XERS transaction

Common Stock

Award

Transaction value: $0
Shares: +100,000
Change %: +170%
Price: $0.000000
Shares after: 158,858
Date: 28 Jul 2021
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These restricted stock units vest in three substantially equal annual installments beginning on July 28, 2022.

SEC remarks

Chief Financial Officer